Factors influencing the performance of patient specific quality assurance for pencil beam scanning IMPT fields.
OBJECTIVE
A detailed analysis of 2728 intensity modulated proton therapy (IMPT) fields that were clinically delivered to patients between 2007 and 2013 at Paul Scherrer Institute (PSI) was performed. The aim of this study was to analyze the results of patient specific dosimetric verifications and to assess possible correlation between the quality assurance (QA) results and specific field metrics.


METHODS
Dosimetric verifications were performed for every IMPT field prior to patient treatment. For every field, a steering file was generated containing all the treatment unit information necessary for treatment delivery: beam energy, beam angle, dose, size of air gap, nuclear interaction (NI) correction factor, number of range shifter plates, number of Bragg peaks (BPs) with their position and weight. This information was extracted and correlated to the results of dosimetric verification of each field which was a measurement of two orthogonal profiles using an orthogonal ionization chamber array in a movable water column.


RESULTS
The data analysis has shown more than 94% of all verified plans were within defined clinical tolerances. The differences between measured and calculated dose depend critically on the number of BPs, total thickness of all range shifter plates inserted in the beam path, and maximal range. An increase of the dose difference was observed with smaller number of BPs (i.e., smaller tumor) and smaller ranges (i.e., superficial tumors). The results of the verification do not depend, however, on the prescribed dose, NI correction, or the size of the air gap. There is no dependency of the transversal and longitudinal spot position precision on the beam angle. The value of NI correction depends on the number of spots and number of range shifter plates.


CONCLUSIONS
The presented study has shown that the verification method used at Centre for Proton Therapy at Paul Scherrer Institute is accurate and reproducible for performing patient specific QA. The results confirmed that the dose discrepancy is dependent on the size and location of the tumor.
Centre for Proton Therapy, Paul Scherrer Institute, PSI West, Villigen 5232, Switzerland.
P
P
Trnková
Centre for Proton Therapy, Paul Scherrer Institute, PSI West, Villigen 5232, Switzerland.
A
A
Bolsi
Centre for Proton Therapy, Paul Scherrer Institute, PSI West, Villigen 5232, Switzerland.
F
F
Albertini
Centre for Proton Therapy, Paul Scherrer Institute, PSI West, Villigen 5232, Switzerland and Radiation Oncology Department, University of Zürich, Rämistrasse 71, Zürich 8006, Switzerland.
D C
DC
Weber
Centre for Proton Therapy, Paul Scherrer Institute, PSI West, Villigen 5232, Switzerland and Department of Physics, ETH Zürich, Rämistrasse 101, Zürich 8092, Switzerland.
A J
AJ
Lomax
D006801:Humans; D057285:Precision Medicine; D061766:Proton Therapy / Q000295:instrumentation / Q000592:standards*; D011785:Quality Assurance, Health Care; D011874:Radiometry; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D050397:Radiotherapy, Intensity-Modulated / Q000295:instrumentation / Q000592:standards*